(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Oct. 31, 2024 (GLOBE NEWSWIRE) -- The "Cancer Antibody Drug Conjugates market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has ...

Q3 2024 Earnings Call Transcript October 30, 2024 GSK plc beats earnings expectations. Reported EPS is $1.29, expectations were $1.23. Operator: Hello, everyone. Welcome to today’s call and webcast.

Blenrep, Depemokimab, Nucala for COPD, Gepotidacin, and our new vaccine to prevent meningitis (MenABCWY).' Sheena Berry, an analyst at Quilter Cheviot, said: 'GSK’s third quarter results for ...

GSK sales hampered by slump in demand for key vaccine - The drugmaker said sales of Arexvy fell sharply in the third quarter, ...

A solid showing for HIV drugs sold by majority-owned ViiV Healthcare and speciality medicines like cancer therapies Zejula ...

GSK declared a third-quarter dividend of 15.00 pence per share, unchanged from the second quarter, but up 7.1% from 14.00p per share last year. It continues to expect a total dividend of 60.00p per ...

Blenrep, a treatment for cancer, and asthma medicine Depemokimab are among the planned new launches. Nonetheless, shares in the company fell after it cut its outlook for its annual vaccines sales ...

Back in late 2022, GSK pulled the multiple myeloma ADC Blenrep from the U.S. market merely days after announcing a phase 3 trial flop. The British pharma is now aiming to reintroduce the drug in ...